These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28057482)

  • 21. Managing emerging mutagenicity risks: Late stage mutagenic impurity control within the atovaquone second generation synthesis.
    Urquhart MWJ; Bardsley B; Edwards AJ; Giddings A; Griva E; Harvey J; Hermitage S; King F; Leach S; Lesurf C; McKinlay C; Oxley P; Pham TN; Simpson A; Smith E; Stevenson N; Wade C; White A; Wooster N
    Regul Toxicol Pharmacol; 2018 Nov; 99():22-32. PubMed ID: 30118726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analyses.
    Amberg A; Andaya RV; Anger LT; Barber C; Beilke L; Bercu J; Bower D; Brigo A; Cammerer Z; Cross KP; Custer L; Dobo K; Gerets H; Gervais V; Glowienke S; Gomez S; Van Gompel J; Harvey J; Hasselgren C; Honma M; Johnson C; Jolly R; Kemper R; Kenyon M; Kruhlak N; Leavitt P; Miller S; Muster W; Naven R; Nicolette J; Parenty A; Powley M; Quigley DP; Reddy MV; Sasaki JC; Stavitskaya L; Teasdale A; Trejo-Martin A; Weiner S; Welch DS; White A; Wichard J; Woolley D; Myatt GJ
    Regul Toxicol Pharmacol; 2019 Mar; 102():53-64. PubMed ID: 30562600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development.
    Harvey J; Fleetwood A; Ogilvie R; Teasdale A; Wilcox P; Spanhaak S
    Regul Toxicol Pharmacol; 2017 Mar; 84():116-123. PubMed ID: 28038978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. It's difficult, but important, to make negative predictions.
    Williams RV; Amberg A; Brigo A; Coquin L; Giddings A; Glowienke S; Greene N; Jolly R; Kemper R; O'Leary-Steele C; Parenty A; Spirkl HP; Stalford SA; Weiner SK; Wichard J
    Regul Toxicol Pharmacol; 2016 Apr; 76():79-86. PubMed ID: 26785392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico prediction of chemical Ames mutagenicity.
    Xu C; Cheng F; Chen L; Du Z; Li W; Liu G; Lee PW; Tang Y
    J Chem Inf Model; 2012 Nov; 52(11):2840-7. PubMed ID: 23030379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved in silico prediction of carcinogenic potency (TD50) and the risk specific dose (RSD) adjusted Threshold of Toxicological Concern (TTC) for genotoxic chemicals and pharmaceutical impurities.
    Contrera JF
    Regul Toxicol Pharmacol; 2011 Feb; 59(1):133-41. PubMed ID: 20933038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative weight of evidence method for combining predictions of quantitative structure-activity relationship models.
    Tintó-Moliner A; Martin M
    SAR QSAR Environ Res; 2020 Apr; 31(4):261-279. PubMed ID: 32065534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of published DNA reactivity alerts.
    Myden A; Guesne SJ; Cayley A; Williams RV
    Regul Toxicol Pharmacol; 2017 Aug; 88():77-86. PubMed ID: 28549899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Consultancy Activity on In Silico Models for Genotoxic Prediction of Pharmaceutical Impurities.
    Pavan M; Kovarich S; Bassan A; Broccardo L; Yang C; Fioravanzo E
    Methods Mol Biol; 2016; 1425():511-29. PubMed ID: 27311479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative evaluation of 11 in silico models for the prediction of small molecule mutagenicity: role of steric hindrance and electron-withdrawing groups.
    Ford KA; Ryslik G; Chan BK; Lewin-Koh SC; Almeida D; Stokes M; Gomez SR
    Toxicol Mech Methods; 2017 Jan; 27(1):24-35. PubMed ID: 27813437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
    Müller L; Singer T
    Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic toxicity assessment: employing the best science for human safety evaluation part III: the comet assay as an alternative to in vitro clastogenicity tests for early drug candidate selection.
    Witte I; Plappert U; de Wall H; Hartmann A
    Toxicol Sci; 2007 May; 97(1):21-6. PubMed ID: 17204584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of pharmaceutical ICH M7 (Q)SAR predictions - The impact of model updates.
    Hasselgren C; Bercu J; Cayley A; Cross K; Glowienke S; Kruhlak N; Muster W; Nicolette J; Reddy MV; Saiakhov R; Dobo K
    Regul Toxicol Pharmacol; 2020 Dec; 118():104807. PubMed ID: 33058939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic toxicity assessment: employing the best science for human safety evaluation. Part I: Early screening for potential human mutagens.
    Jacobson-Kram D; Contrera JF
    Toxicol Sci; 2007 Mar; 96(1):16-20. PubMed ID: 17194803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Derivation and validation of toxicophores for mutagenicity prediction.
    Kazius J; McGuire R; Bursi R
    J Med Chem; 2005 Jan; 48(1):312-20. PubMed ID: 15634026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Good statistics practice (GSP) in genetic toxicology.
    Khromov-Boris NN; Pêgas Henriques JA
    Mutat Res; 1998 Aug; 405(1):97-108. PubMed ID: 9729304
    [No Abstract]   [Full Text] [Related]  

  • 37. Random forest prediction of mutagenicity from empirical physicochemical descriptors.
    Zhang QY; Aires-de-Sousa J
    J Chem Inf Model; 2007; 47(1):1-8. PubMed ID: 17238242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. QSAR models to predict mutagenicity of acrylates, methacrylates and alpha,beta-unsaturated carbonyl compounds.
    Pérez-Garrido A; Helguera AM; Rodríguez FG; Cordeiro MN
    Dent Mater; 2010 May; 26(5):397-415. PubMed ID: 20122717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative evaluation of in silico systems for ames test mutagenicity prediction: scope and limitations.
    Hillebrecht A; Muster W; Brigo A; Kansy M; Weiser T; Singer T
    Chem Res Toxicol; 2011 Jun; 24(6):843-54. PubMed ID: 21534561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of In Silico Methods for Regulatory Toxicological Assessment of Pharmaceutical Impurities.
    Kovarich S; Cappelli CI
    Methods Mol Biol; 2022; 2425():537-560. PubMed ID: 35188646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.